Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has recently published a peer-reviewed article in the Journal of Dermatological Treatment, highlighting the disease-modifying potential of PC111, a first-in-class human anti-Fas Ligand monoclonal antibody. The study's findings demonstrate PC111's ability to prevent blister formation in humanized models of pemphigus by targeting soluble Fas Ligand, presenting a novel, non-immunosuppressive approach to treatment. Additionally, the data suggests potential applications in treating Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN), a severe and life-threatening dermatological condition.
Amir Reichman, CEO of Scinai Immunotherapeutics, emphasized that these findings underscore PC111's capability to revolutionize treatment options for these conditions, which currently have high unmet medical needs. The publication of this data not only marks a significant milestone for Scinai but also opens new avenues for therapeutic interventions in dermatology, potentially improving patient outcomes and offering significant value to shareholders.
For further details on the study and its implications, the full press release can be accessed here.
